Presenter of 3 Presentations
Q&A
Use of the Omnipod® 5 System: Clinical Data Updates on Broad Patient Cohorts
CONTINUOUS GLUCOSE MONITORING IN TYPE 2 DIABETES: DEMOGRAPHICS AND CHARACTERIZATION OF USE ACROSS A LARGE INTEGRATED HEALTHCARE SYSTEM
Abstract
Background and Aims
Continuous glucose monitoring (CGM) use in type 2 diabetes (T2D) is expanding despite limited data about real-world use. HealthPartners is a large integrated healthcare system containing clinical and insurance claims data for member-patients. This analysis describes clinical characteristics of member-patients prescribed CGM.
Methods
A retrospective, observational chart and claims review was conducted for T2D patients prescribed CGM, who receive care and insurance through HealthPartners. Aims: 1) describe pre-CGM to post-CGM changes in HbA1c; 2) describe medication patterns pre-CGM to post-CGM; 3) quantify associations of change in HbA1c with CGM usage and demographics.
Results
From January 1, 2018 to December 31, 2020, CGM was prescribed to 2231 T2D patients (9.4% of total T2D population). 93.2% of prescriptions were filled (84% filled within 30 days). Pre-CGM HbA1c (closest HbA1c 0-6 months prior) was 8.9%+/-2.1%, versus post-CGM (closest HbA1c 8 weeks-12 months after CGM) 8.0%+/-1.7% (p=<0.0001). Pre-CGM, HbA1c <8.0% in 35.6% of patients, versus 52.8% post-CGM. GLP-1 agonist use increased regardless of baseline HbA1c; analog insulin use increased if pre-CGM HbA1c was >10%. Sulfonylurea use decreased if HbA1c <10%. Male sex, age, and filling CGM <30 days demonstrated significant HbA1c decrease; BMI, race, and number of medications did not correlate with HbA1c.
Conclusions
In a large cohort of patients with T2D, HbA1c decreased after filling CGM. Medication patterns also changed, suggesting CGM influenced therapeutic adjustments and possibly contributed to reducing HbA1c. Those who filled their CGM sooner saw the largest decrease in HbA1c, suggesting early patient engagement may be important for successful CGM use in T2D.